Corvus Pharma formed a China subsidiary, Angel Pharma, to develop its three clinical stage assets and one preclinical platform in China . Angel will have a post-money value of $106 million. Corus will own 49.7% of Angel, while three China biopharma investors will invest $41 million for the rest. The investors are Tigermed-Betta Pharma, Hisun Pharma and Zhejiang Puissance Capital. Angel will have China rights to three Corvus clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and global rights to Corvus’ BTK inhibitor preclinical programs. More details.... Stock Symbol: (NSDQ: CRVS) Share this with colleagues: // //